Dr. Ben Starnes to Present Early Data on AortaFit™ System at International Symposium at Charing Cross

Initial Use of Predictive Software & 3D printed planning tool to Personalize Treatment of AAA disease and Simplify Fenestrated EVAR

BELLEVUE, Wash.--()--Aortica Corporation today announced that Dr. Benjamin Starnes, Chief of Vascular Surgery at the University of Washington (UW) will present his early clinical experience with Aortica Corporation’s AortaFit™ System at the International Symposium at Charing Cross in London England. The AortaFit™ System is an investigational surgical planning tool comprised of Aortica’s Fenestration Alignment Software and a patient-specific 3D printed fenestration template. Dr. Starnes received FDA approval to begin use of the AortaFit System in his physician-sponsored IDE study in late January and has since used the system to treat 5 patients with complex abdominal aortic aneurysms (AAA). The presentation in London is titled ‘3-D Printed Aortic Models for FEVAR’ and will focus on Dr. Starnes’ procedural results and follow up out to 30 days.

“I am very encouraged by these early results and look forward to sharing them with the attendees at Charing Cross”

“I am very encouraged by these early results and look forward to sharing them with the attendees at Charing Cross,” stated Dr. Starnes. “The Aortica software dramatically simplifies the upfront planning for fenestrated EVAR (FEVAR) procedures, which has been a significant hurdle for surgeons who otherwise want to perform FEVAR. In each of these cases we generated 3-fenestration templates that precisely matched the anatomical requirements of each patient. We then easily modified grafts from three different graft manufacturers. The alignment of the fenestrations was perfect and the grafts were easily placed.”

About Abdominal Aortic Aneurysm (AAA) Disease

Each year between 150,000 and 180,000 people in the United States are diagnosed with abdominal aortic aneurysms (AAA). An aneurysm is a large bulge in the aorta (the largest artery in the human body). It can gradually expand over time—without any symptoms—until it bursts, causing massive internal bleeding that results in death if not treated at a specialized center immediately. For years, major open surgery was the only treatment option, which is risky due to its complicated nature and because it carries a 3.0% mortality rate within 30 days of surgery.

About Endovascular Aneurysm Repair (EVAR)

In the 1990’s, a new technique for controlling aneurysms was developed using a graft inserted through the femoral arteries. This technique is called endovascular aneurysm repair (EVAR). EVAR is significantly less invasive than open surgery and is associated with a mortality rate six times lower. Patients recover faster, leave the hospital sooner, and return to activities of normal daily life more quickly. Consequently, EVAR has become the gold standard for treatment of AAA disease.

About Aortica Corporation

Aortica Corporation was founded to design, manufacture, and market tools for treatment of patients with AAA disease who have aortic anatomy that limits their treatment options. While EVAR has become a highly desirable option for treatment of AAA disease, approximately 40% of patients are not candidates for EVAR because their aortic anatomy is structured in a manner that does not allow an endograft to be anchored properly without blocking blood flow to vital organs. These patients face either open surgery or may be treated sub-optimally with standard EVAR. Aortica is dedicated to simplifying Fenestrated EVAR (FEVAR), and advancing the science of Personalized Vascular Therapy.

For further information visit the company’s website at www.aorticacorp.com

Contacts

Aortica Corporation
Stacy Douthitt, 425-209-0023
stacydouthitt@aorticacorp.com

Recent Stories

RSS feed for Aortica Corporation

Release Summary

Dr. Starnes presents early clinical experience with Aortica Corporation’s AortaFit™ System at the International Symposium at Charing Cross in London England.

Aortica Corporation